Boundless Bio, Inc.(BOLD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BOLD Boundless Bio, Inc.

Closed 12-18 16:00:00 EST

1.27

+0.00

0.00%

盘后1.26

-0.01-0.79%

19:21 EST

High1.37	Low1.14	Vol503.92K
Open1.26	D1 Closing1.27	Amplitude18.11%
Mkt Cap28.43M	Tradable Cap20.91M	Total Shares22.39M
T/O643.07K	T/O Rate3.06%	Tradable Shares16.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BOLD","market":"US","secType":"STK","nameCN":"Boundless Bio, Inc.","latestPrice":1.27,"timestamp":1766091600000,"preClose":1.27,"halted":0,"volume":503922,"hourTrading":{"tag":"盘后","latestPrice":1.26,"preClose":1.27,"latestTime":"19:21 EST","volume":10351,"amount":13043.2202,"timestamp":1766103666238},"delay":0,"floatShares":16462050,"shares":22385611,"eps":-2.764393,"marketStatus":"Closed","change":0,"latestTime":"12-18 16:00:00 EST","open":1.26,"high":1.37,"low":1.14,"amount":643073.509314,"amplitude":0.181102,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.764393,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1711598400000,"exchange":"NASDAQ","adjPreClose":1.27,"preHourTrading":{"tag":"盘前","latestPrice":1.24,"preClose":1.27,"latestTime":"09:22 EST","volume":150,"amount":187.00000500000002,"timestamp":1766067743084},"postHourTrading":{"tag":"盘后","latestPrice":1.26,"preClose":1.27,"latestTime":"19:21 EST","volume":10351,"amount":13043.2202,"timestamp":1766103666238},"volumeRatio":4.061928},"requestUrl":"/m/hq/s/BOLD/tweets","defaultTab":"tweets","newsList":[{"id":"2585461626","title":"Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461626","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585461626?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov.  24, 2025  (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/24/3193371/0/en/Boundless-Bio-to-Participate-in-the-Piper-Sandler-37th-Annual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2413666426.HKD","BK4588","LU0077335932.USD","LU0029874061.USD","XLV","LU1721428933.USD","LU2244417387.USD","LU0187121727.USD","BK4139","BK4137","LABU","RNR","XBI","BK4019","LU0347712357.USD","BK4581","HCSG","BOLD","BK4585","LU0128526141.USD","LU2413666699.HKD"],"gpt_icon":0},{"id":"2582801089","title":"Boundless Bio Unveils New Therapies Targeting ecDNA-Driven Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582801089","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582801089?lang=en_us&edition=fundamental","pubTime":"2025-11-11 02:51","pubTimestamp":1762800661,"startTime":"0","endTime":"0","summary":"Boundless Bio Inc. has released a corporate presentation detailing its latest advancements in cancer treatment through ecDNA-directed therapies . The company highlights the significant unmet medical need for therapies targeting oncogene amplified cancers, which are generally unresponsive to existing targeted and immunotherapies. Boundless Bio's approach leverages extrachromosomal DNA , identified as a key driver of oncogene amplification in cancer. The presentation outlines the company's clinical-stage candidates, including BBI-355, an oral CHK1 inhibitor, and BBI-825, an oral RNR inhibitor, both being evaluated in the POTENTIATE clinical trial. Additionally, BBI-940, an oral Kinesin degrader, is expected to begin clinical trials in the first half of 2026. According to the company, approximately 25% of cancer patients have amplified oncogenes, with about half of high-copy number amplifications occurring on ecDNA. There are currently no approved therapies for these cancers, except for H","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL7ppXqg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOLD","BK4139"],"gpt_icon":0},{"id":"2581721499","title":"Boundless Bio Q3 EPS $(0.62) Misses $(0.53) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581721499","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581721499?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:08","pubTimestamp":1762344491,"startTime":"0","endTime":"0","summary":"Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.53) by 16.32 percent. This is a 16.22 percent increase over losses of $(0.74) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48649313/boundless-bio-q3-eps-0-62-misses-0-53-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOLD"],"gpt_icon":0},{"id":"2581072172","title":"Boundless Bio Inc: Qtrly EPS $-0.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2581072172","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581072172?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344007,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA1RX9ZG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2581722229","title":"Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722229","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722229?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344000,"startTime":"0","endTime":"0","summary":"Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial  Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3181282/0/en/Boundless-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2413666699.HKD","BK4139","LU0347712357.USD","LU2413666426.HKD","LU0077335932.USD","BK4019","LU1721428933.USD","LU2244417387.USD","RNR","LU0187121727.USD","BOLD"],"gpt_icon":0},{"id":"2575280607","title":"Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2575280607","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575280607?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:05","pubTimestamp":1760385900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct.  13, 2025  (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165792/0/en/Boundless-Bio-Announces-Upcoming-Presentation-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1584","LU0187121727.USD","BK1550","LU0077335932.USD","LU1721428933.USD","NCI","RNR","LU0572939691.SGD","BK4007","01336","BK4539","LENZ","BK1184","LU2413666699.HKD","BOLD","LU2244417387.USD","LU0264606111.USD","LU0347712357.USD","LU2413666426.HKD","LU0572940350.SGD","BK4019","BK4139","BK4202"],"gpt_icon":0},{"id":"2569688317","title":"ESQUIRE VIETNAM RELAUNCHES WITH A BOLD VISION, CELEBRATING THE AGE OF EXCELLENCE","url":"https://stock-news.laohu8.com/highlight/detail?id=2569688317","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569688317?lang=en_us&edition=fundamental","pubTime":"2025-09-23 10:56","pubTimestamp":1758596160,"startTime":"0","endTime":"0","summary":"HO CHI MINH CITY, Vietnam, Sept. 23, 2025 /PRNewswire/ -- Esquire Vietnam officially marks its bold return with a refreshed vision and renewed identity. The relaunch celebrates modern masculinity and honors trailblazers shaping Vietnam's cultural and creative landscape.Pictured at the event: Venus Tran , Founder & CEO of Sun Flower Media, and Dan Q. Dao , Editor-in-Chief.The unveiling of Esquire Vietnam’s return cover, featuring actor Lien Binh Phat.","market":"us","thumbnail":"https://mma.prnewswire.com/media/2778422/image_5053589_32675033.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2778422/image_5053589_32675033.jpg?w=300"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/esquire-vietnam-relaunches-with-a-bold-vision-celebrating-the-age-of-excellence-302563757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOLD"],"gpt_icon":0},{"id":"2557604395","title":"Boundless Bio Q2 EPS $(0.70) Beats $(0.71) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2557604395","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557604395?lang=en_us&edition=fundamental","pubTime":"2025-08-05 19:25","pubTimestamp":1754393133,"startTime":"0","endTime":"0","summary":"Boundless Bio Q2 EPS $(0.70) Beats $(0.71) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46853281/boundless-bio-q2-eps-0-70-beats-0-71-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOLD"],"gpt_icon":0},{"id":"2557393403","title":"Boundless Bio Inc. Reports Q2 2025 Results: Net Loss Narrows to $15.7M, R&D Expenses Decrease to $12.2M","url":"https://stock-news.laohu8.com/highlight/detail?id=2557393403","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557393403?lang=en_us&edition=fundamental","pubTime":"2025-08-05 19:06","pubTimestamp":1754391969,"startTime":"0","endTime":"0","summary":"Boundless Bio Inc. , a clinical-stage oncology company, reported financial results for the second quarter ending June 30, 2025. The company announced a net loss of $15.7 million, compared to a net loss of $17.0 million for the same period in 2024. Research and Development expenses decreased to $12.2 million, down from $14.7 million in the previous year. General and Administrative expenses slightly increased to $4.8 million from $4.7 million in the second quarter of 2024. The company maintains a strong cash position, with cash, cash equivalents, and short-term investments totaling $127.1 million as of June 30, 2025. This financial health is expected to support operations into the first half of 2028, allowing for expected proof-of-concept clinical readouts for its programs. In terms of business updates, Boundless Bio has opened the combination arm of the POTENTIATE trial for enrollment and is on track to submit an investigational new drug application for BBI-940 in the first half of 2026","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nNDL3NpB2k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2557739397","title":"Boundless Bio: Bbi-940 Is on Track for Submission of Investigational New Drug Application in H1 of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2557739397","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557739397?lang=en_us&edition=fundamental","pubTime":"2025-08-05 19:00","pubTimestamp":1754391600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nTUA7XHY3F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2545344741","title":"Boundless Bio Inc. Concluded Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2545344741","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545344741?lang=en_us&edition=fundamental","pubTime":"2025-06-24 04:22","pubTimestamp":1750710145,"startTime":"0","endTime":"0","summary":"Boundless Bio Inc. held its annual meeting of stockholders on June 23, 2025. During the meeting, two proposals were voted on. The first proposal involved the election of director nominees Christine Brennan, Ph.D., and Nancy Whiting, Pharm.D., both of whom were elected as Class I directors. The second proposal, which involved the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 23","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDLb76CkW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BOLD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.boundlessbio.com","stockEarnings":[{"period":"1week","weight":0.0948},{"period":"1month","weight":0.0763},{"period":"3month","weight":0.114},{"period":"6month","weight":0.2212},{"period":"1year","weight":-0.498},{"period":"ytd","weight":-0.5621}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing four products, including AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia; and AT982 for the treatment of pompe disease. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania to develop AT342, an AAV gene therapy for Crigler-Najjar Syndrome, an inherited, metabolic liver disease. The company was founded in 2012 and is based in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.045467},{"month":2,"riseRate":0.25,"avgChangeRate":0.036219},{"month":3,"riseRate":0.666667,"avgChangeRate":0.088311},{"month":4,"riseRate":0.333333,"avgChangeRate":0.028717},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.032827},{"month":6,"riseRate":1,"avgChangeRate":0.142257},{"month":7,"riseRate":0.666667,"avgChangeRate":0.021175},{"month":8,"riseRate":0.5,"avgChangeRate":-0.031707},{"month":9,"riseRate":0.75,"avgChangeRate":0.116011},{"month":10,"riseRate":0,"avgChangeRate":-0.120737},{"month":11,"riseRate":0.75,"avgChangeRate":0.014772},{"month":12,"riseRate":0.75,"avgChangeRate":0.282026}],"exchange":"NASDAQ","name":"Boundless Bio, Inc.","nameEN":"Boundless Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Boundless Bio, Inc.(BOLD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Boundless Bio, Inc.(BOLD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Boundless Bio, Inc.,BOLD,Boundless Bio, Inc.股票,Boundless Bio, Inc.股票老虎,Boundless Bio, Inc.股票老虎国际,Boundless Bio, Inc.行情,Boundless Bio, Inc.股票行情,Boundless Bio, Inc.股价,Boundless Bio, Inc.股市,Boundless Bio, Inc.股票价格,Boundless Bio, Inc.股票交易,Boundless Bio, Inc.股票购买,Boundless Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Boundless Bio, Inc.(BOLD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Boundless Bio, Inc.(BOLD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction